Clinical trials: Antifungal Agents
Antifungal Agents
Screening Anti-Fungal Exposure in Intensive Care Units
Adequate antifungal therapy is a critical determinant of survival in patients admitted to an Intensive Care Unit (ICU) with suspected or proven fungal infections.
- Trial name
- SAFE-ICU (NCT03136926)
- Where
- 47 sites in United States, Australia and 11 more
- Volunteers
- 150 people
- Sponsor
- The University of Queensland
Fungal Infection, Leukemia
Empirical Versus Preemptive Antifungal Therapy
RATIONALE: Caspofungin acetate may be effective in treating fungal infections in patients with acute myeloid leukemia or myelodysplastic syndrome who are receiving treatment for their cancer.
- Conditions
- Fungal Infection, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT01288378
- Testing
- caspofungin acetate
- Where
- 16 sites in Belgium, Czechia and 4 more
- Volunteers
- 556 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Tinea Pedis
Topical Antifungal Treatment for Tinea Pedis
The purpose of this study is to determine if a topical antifungal cream is safe and effective for the treatment of tinea pedis.
- Trial name
- NCT01396785
- Testing
- 33525
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 321 people
- Sponsor
- Medicis Global Service Corporation
Antifungal Prophylaxis of Invasive Fungal Infections
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.
- Trial name
- IMPROVIT (NCT00289991)
- Testing
- Itraconazole, Vfend - voriconazole
- Where
- 49 sites in Canada, Czechia and 10 more
- Volunteers
- 489 people
- Sponsor
- Pfizer
Leukemia, Myelodysplastic Syndrome
Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease
The purpose of this study is to study the pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Leukemia, Myeloid, Acute
- Trial name
- ANIDULAPK (NCT01249820)
- Testing
- anidulafungin 200 mg q48h, anidulafungin 300 mg q72h
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Radboud University Medical Center